Adding local treatment after immunotherapy for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests whether giving focused local treatment (like radiation or surgery) after a combination of two drugs, sintilimab and lenvatinib, can help control advanced liver cancer that has spread to a few other places. The goal is to see if this approach can shrink tumors and possibly extend life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have advanced liver cancer (hepatocellular carcinoma) that has spread to 1 to 5 spots outside the liver, involving no more than 2 other organs.
- You should not have received any previous treatment for advanced liver cancer, like immunotherapy or targeted pills.
- You need to be in good general health (able to do light activities) and have adequate liver and kidney function.
- You must not have major blood vessel invasion in the liver or a liver that is too full of tumors to treat locally.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining an immunotherapy drug (sintilimab) with a targeted therapy (lenvatinib) after surgical removal of liver cancer can help prevent the cancer from coming back. It is for patients whose tumors show a specific blood vessel pattern called VETC.
This trial tests a combination treatment for advanced liver cancer that cannot be removed with surgery. It combines a procedure (irreversible electroporation) that uses electrical pulses to destroy cancer cells, with targeted therapy (lenvatinib) and immunotherapy (sintilimab) to help your immune system fight the cancer.
This trial tests whether giving an immunotherapy drug (sintilimab) after surgery helps keep liver cancer with microscopic blood vessel invasion from coming back. It may improve chances of staying cancer-free after surgery.
This trial tests whether giving two medicines (an immunotherapy and a targeted therapy) after surgery can help prevent liver cancer from coming back in people with a specific type of tumor clot in the liver's main vein. If you've had surgery to remove the cancer and meet the health criteria, this treatment may lower your risk of recurrence.
This study tests a new approach: giving two immunotherapy drugs (sintilimab and ipilimumab) along with treatments that block blood flow to the tumor (TACE or ablation) before surgery for liver cancer that is at high risk of coming back. The goal is to see if this combination can shrink the tumor and reduce the chance of recurrence after surgery.
This study looks at how adding local treatments (like targeted radiation or chemotherapy directly to the liver tumor) to your current immunotherapy and targeted therapy combination might affect outcomes for people with advanced liver cancer. It aims to find out which patients benefit most from adding these extra treatments.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.